Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children-Reference-Cited by-同舟云学术

Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children

Published:2020-03-11 Issue:8 Volume:59 Page:1049-1061
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Marsit Hanen,Philippe Michaël,Neely Michael,Rushing Teresa,Bertrand Yves,Ducher Michel,Leclerc Vincent,Guitton Jérôme,Bleyzac Nathalie,Goutelle Sylvain

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40262-020-00877-z.pdf

Reference39 articles.

1. Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016;3(11):e526–36. https://doi.org/10.1016/S2352-3026(16)30114-4.

2. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo CIV. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transpl. 2004;33(10):979–87. https://doi.org/10.1038/sj.bmt.1704446.

3. Buffery PJ, Allen KM, Chin PK, Moore GA, Barclay ML, Begg EJ. Thirteen years’ experience of pharmacokinetic monitoring and dosing of busulfan: can the strategy be improved? Ther Drug Monit. 2014;36(1):86–92. https://doi.org/10.1097/FTD.0b013e31829dc940.

4. Philippe M, Goutelle S, Guitton J, Fonrose X, Bergeron C, Girard P, et al. Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children. Bone Marrow Transpl. 2016;51(1):72–8. https://doi.org/10.1038/bmt.2015.218.

5. Choong E, Uppugunduri CRS, Marino D, Kuntzinger M, Doffey-Lazeyras F, Lo Piccolo R, et al. Therapeutic drug monitoring of busulfan for the management of pediatric patients: cross-validation of methods and long-term performance. Ther Drug Monit. 2018;40(1):84–92. https://doi.org/10.1097/FTD.0000000000000468.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT);Bone Marrow Transplantation;2024-09-13

2. Busulfan Exposure Target Attainment in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation: A Single Day Versus a Multiple Day Therapeutic Drug Monitoring Regimen;Transplantation and Cellular Therapy;2024-07

3. Simulation-Based Optimization of Sampling Schedules for Model-Informed Precision Dosing of Once-Daily and 4-Times-Daily Busulfan in Pediatric Patients;Therapeutic Drug Monitoring;2024-06-14

4. Model-Informed Precision Dosing of Intravenous Busulfan in Thai Pediatrics Undergoing Hematopoietic Stem Cell Transplantation;Therapeutic Drug Monitoring;2024-05-14

5. Impact of prophylactic echinocandin on the development of neurological complications in patients receiving busulfan‐containing conditioning regimens for stem cell transplantation: A single‐center retrospective study;Pediatric Transplantation;2024-04-10